Aimmune Therapeutics (AIMT) Tops Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
May 11, 2020 4:05 PM EDTContinues to be launch ready for PALFORZIATM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply for all ongoing clinical trials $371.6 million cash, cash equivalents and investments on-hand and implementing numerous cash-preservation measures Webcast and conference call today at 4:30 p.m. ETÂ
Â
BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for... More
